Go Deep
Gossamer Bio, Inc.
Gossamer Bio, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -18,028 | -0.2 | -0.58 | -1.65 | 842.02 |
| Oct 2026 | -18,023 | -0.2 | -0.57 | -1.65 | 830.65 |
| Oct 2026 | -19,806 | -0.2 | -0.55 | -1.65 | 799.30 |
| Oct 2026 | -19,862 | -0.2 | -0.62 | -1.65 | 908.34 |
| Oct 2026 | -19,872 | -0.2 | -0.64 | -1.65 | 925.96 |
| Oct 2026 | -19,856 | -0.2 | -0.61 | -1.65 | 892.94 |
Gossamer Bio, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 9,238,000.0 | 16,955,000.0 | 13,799,000.0 | 13,294,000.0 |
| Net Profit | 16,900,000.0 | -46,664,000.0 | -47,238,000.0 | -48,221,000.0 |
| EPS | 4.0 | -16.0 | -16.8 | -16.8 |
Gossamer Bio, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 48,471,000.0 | 114,701,000.0 | 0.0 | 0.0 | — |
| Net Profit | -170,370,000.0 | -56,528,000.0 | -179,817,000.0 | -229,378,000.0 | — |
| EPS | -60.0 | -20.0 | -94.4 | -216.8 | — |
Gossamer Bio, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 172,249,000.0 | 315,292,000.0 | 311,916,000.0 | 272,450,000.0 | — |
| Total Liabilities | 295,009,000.0 | 285,800,000.0 | 249,147,000.0 | 260,373,000.0 | — |
| Total Equity | -122,760,000.0 | 29,492,000.0 | 62,769,000.0 | 12,077,000.0 | — |
Owes vs Owns
Gossamer Bio, Inc. owed $2.22 for every $1 it owned in Jun 2026, up from $0.96 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 2.22× | 1.71× | 0.91× | 0.80× | 0.96× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Gossamer Bio, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 79.5%Receivables 7.1%Fixed assets (tangible) 2.4%Other assets 11.0%
How it's funded — Dec 2025
Long-term debt 67.3%Payables 2.0%Other liabilities 30.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 136.9 | 294.5 | 296.4 | 255.7 |
| Receivables | 12.2 | 5.3 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 4.2 | 5.1 | 4.8 | 9.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 18.9 | 10.3 | 10.7 | 6.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.9 | 1.0 | 11.6 | 11.6 |
| Long-term debt | 198.5 | 197.5 | 197.4 | 207.7 |
| Payables | 6.0 | 2.3 | 5.5 | 1.5 |
| Other liabilities | 89.6 | 85.0 | 34.6 | 39.6 |
| Shareholders' equity | -122.8 | 29.5 | 62.8 | 12.1 |
| Net tangible assets | -122.8 | 29.5 | 62.8 | 12.1 |
Gossamer Bio, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -171,266,000.0 | -3,468,000.0 | -159,158,000.0 | -187,032,000.0 | — |
| Investing Activities | 156,358,000.0 | 29,023,000.0 | -110,970,000.0 | -1,035,000.0 | — |
| Financing Activities | 6,425,000.0 | -11,488,000.0 | 190,154,000.0 | 117,090,000.0 | — |